Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Forest Labs CEO to step aside at year's end after decades at the helm

Forest Laboratories will have a new CEO when 2014 dawns. Longtime chief Howard Solomon will step out of that role on Dec. 31, with plans to stick around as chairman till next year's annual meeting, and as a director for some time after that. In the meantime, Forest's search committee is hunting for a replacement, aiming to name someone before year's end.

Warner Chilcott CEO up for $9.2M handshake after Actavis deal

As the dust settles around Actavis' announced buyout of Warner Chilcott, it's time to dig into some of the nitty-gritty details about "New Actavis." For instance, which of Warner's top people will stick around--and if they don't, how much severance might they collect on the way out? And just how big is the tax cut Actavis expects from making the deal?

Third Rock Ventures adds biotech veterans to team

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Congressional Repubs challenge FDA on deputy commissioner's exit

Just a few months after Leona Brenner-Gati was named Acting Deputy Commissioner for Medical Products and Tobacco to replace the outgoing Steven Spielberg, who served only a brief stint at the post, Brenner-Gati is gone as well.

AbbVie research chief heads for the exits, amid rash of top R&D departures

AbbVie filed forms with the SEC on Friday saying that John Leonard, the company's senior vice president and CSO, will be leaving in the coming months.

AbbVie's senior R&D exec Leonard joins exodus from the top ranks

The epidemic of retirements among top R&D executives is continuing with the news that AbbVie's senior researcher is headed for the exits. AbbVie filed forms with the SEC on Friday saying that John Leonard, the company's senior vice president and CSO will be leaving in the coming months. And the company says that one of his last acts will be advising the company on his successor.

Dunsire out as Takeda rolls Millennium into its global R&D operations

CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization.

UPDATED: Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup

Millennium CEO Deborah Dunsire is retiring and her business development chief Anna Protopapas will step in to head the oncology business of Takeda Pharmaceutical. The Japanese drugmaker revealed the management shakeup in a terse announcement today.

Moderna taps biotech legend Henri Termeer for board of directors

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Ex-Genzyme chief Termeer joins board at Cambridge biotech

Moderna, which struck a major development deal with AstraZeneca just months after it shed stealth status, has landed former Genzyme CEO Henri Termeer for the board of directors